From Wikipedia, the free encyclopedia
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||416.47 g·mol−1 g·mol−1|
|3D model (JSmol)|
Aderbasib (codenamed INCB7839) is a sheddase inhibitor that may suppress tumor cell proliferation. Acting on multiple receptor classes and subclasses, aderbasib is observed to regulate the tumor necrosis factor of cancer cells. Aderbasib was being developed by Incyte as a potential adjunctive treatment for metastatic breast cancer. Development was halted in 2011 after positive findings from Phase II trials were contradicted by further research.
- "STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL" (PDF). Ama-assn.org. Retrieved 2012-10-13.
- "Aderbasib | CAS#791828-58-5". MedKoo. Retrieved 2012-10-13.
- Incyte (2011-09-19). "UBS 2011 Global Life Sciences Conference". Retrieved 2013-02-13.
- "Incyte Reports Third Quarter 2011 Financial Results And Provides Update On Key Clinical Programs" (Press release). BusinessWire. 2011-10-27. Retrieved 2013-02-13.
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.